A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial

William A. Gray(Columbia University Irving Medical Center), Toshiaki Mano, Steve Henao, Thomas Albrecht(Heidelberg University), Christian Loewe(Medical University of Vienna), Andrew Benko(Centre Hospitalier Universitaire de Sherbrooke), Yazan Khatib, Sean Janzer, Jeffery T. Prem(Aultman Hospital), Robert Beasley, Daizo Kawasaki, Stewart Hawkins, Stefan Müller‐Hülsbeck(DIAKO), Safwan Jaalouk, William Bachinsky, Anvar Babaev(Columbia University Irving Medical Center), Robert Feldman, Patrick Hall, Daniel Dulas, Danielle Bajakian, Kenji Andò(Kokura Memorial Hospital), Michael Bacharach, Mark W. Fugate, Mark W. Burket, Michael R. Jaff(Harvard University), Juan Diaz‐Cartelle(Boston Scientific (United States)), Tony Das(Research Institute of Dallas), Koen Keirse, Andrew Holden(University of Auckland), Jeffrey J. Popma(MedStar Washington Hospital Center), Jaafer Golzar, Benjamin J. Herdrich, Ethan C Korngold, Hannes Deutschmann(Medical University of Graz), Rao Gutta, Keisuke Hirano, Yoshiaki Yokoi(Kishiwada Tokushukai Hospital), Randall De Martino, Henrik Schrøeder, James F. Benenati, Lawrence A. Garcia, Louis Lopez, Henry Lui, Kimihiko Kichikawa, Joseph Cardenas, Yoshimitsu Soga(Kokura Memorial Hospital)
The Lancet
September 24, 2018
Cited by 288


Related Papers